氯沙坦对高血压病人部分血管活性肽的影响

目的 :观察氯沙坦降压疗效及其对部分血管活性肽的影响。方法 :4 7例轻、中度高血压病人予氯沙坦 5 0～ 10 0mg ,po ,qd× 4wk ,观察其血压变化 ,并测定血浆血管紧张肽II(AngII)、内皮素(ET)、心钠素 (ANF)和降钙素基因相关肽 (CGRP)治疗前后的变化。结果 :治疗 4wk后 ,高血压病人血压明显下降 (P <0 .0 1)。AngII治疗前后为 (10 3±s 5 0 )ng·L- 1和 (15 0± 85 )ng·L- 1(P <0 .0 1) ,CGRP分别为 (30± 17)ng·L- 1和 (4 5± 18)ng·L- 1(P <0 .0 1) ,均较治疗前升高。ANF则较治疗前降低 ,分别为 (2 75± 17)ng·L- 1和 (186± 7)ng·L- 1(P<0 .0 1)。而血浆ET治疗前后无显著变化 (P >0 .0 5 )。结论 :氯沙坦具有平稳的降压疗效 ,并能影响部分血管活性肽的异常分泌

Effect of losartan on part vascular active peptides in patients with hypertension

AIM: To investigate the effect of losartan on blood pressure, vascular active peptides in patients with essential hypertension. METHODS: Forty seven patients with mild to moderate essential hypertensive patients were given 50 100 mg of losartan once daily for 4 wk. The blood pressure was measured every morning during treatment. At the same time, the serum levels of angiotensin Ⅱ(Ang Ⅱ), endothelins(ET), atrial natriuretic factor(ANF), and calcitonin generelated peptide(CGRP) were measured before and after therapy. RESULTS: Losartan significantly reduced both systolic and diastolic blood pressure SBP(22.0± s 2.4) kPa vs (19.9± 2.4 )kPa, P <0.01;DBP(13.4±1.2) kPa vs (12.4±1.4 ) kPa, P <0.01. Ang II and CGRP were increased respectively, (103±50) ng·L -1 vs (150±85) ng·L -1 , P <0.01;(30±17) ng·L -1 vs (45±18) ng·L -1 , P <0.01) ,while ANF decreased after therapy in patients with hypertension (275±17 )ng·L -1 vs (186±7) ng·L -1 , P <0.01. There were no significantly changes in ET. CONCLUSION: Losartan can lower hypertension persistently and smoothly. Losartan can also affect the unusual excretion of part vascular active peptides in patients with essential hypertension.